Higher cost of Penthrox is not much of a factor except in emerging markets, the safer profile and speed are what drives take up. The roll out has been frustratingly slow and Covid inflicted but long term story has been consistant.
Ann: Investor Presentation - $30m Capital Raise and FY22 Guidance, page-15
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.015(3.80%) |
Mkt cap ! $35.38M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 40.0¢ | $4.842K | 12.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2182 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 5977 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| MVP (ASX) Chart |